Printer Friendly

PROSCAR, NEW DRUG FOR SYMPTOMATIC BENIGN PROSTATE ENLARGEMENT, INTRODUCED AT NATIONAL SATELLITE NEWS CONFERENCE TODAY, 1 P.M.

 PROSCAR, NEW DRUG FOR SYMPTOMATIC BENIGN PROSTATE ENLARGEMENT,
 INTRODUCED AT NATIONAL SATELLITE NEWS CONFERENCE TODAY, 1 P.M.
 WHAT: A national satellite press conference to report on a new drug to treat symptomatic benign prostate enlargement, a common condition in the majority of men over 50 years of age.
 WHO:
 -- Dr. E. Darracott Vaughan, professor of urology, and director of division of urology, Cornell University Medical College.
 -- Dr. Elizabeth Stoner, executive director of clinical research, Merck Research Laboratories.
 -- Dr. Edward M. Scolnick, president, Merck Research Laboratories, and senior vice president, Merck & Co., Inc.
 WHEN: Today (Monday, June 22), 1:00 p.m.
 WHERE: Jade Room, Waldorf Astoria, 301 Park Ave., New York
 WHY: Some 10 million American men -- over half of all men over 50 -- suffer some symptoms of benign prostate enlargement, a condition that squeezes the urinary tube, blocking the flow of urine and causing persistent discomfort and distress. In rare cases, it can lead to bladder or kidney damage. And over 400,000 American men a year have symptoms severe enough to require surgery. Yet, it's a condition many men suffer privately out of embarrassment.
 Proscar is the first of a new class of prescription drugs to treat symptomatic benign prostate enlargement. The drug has been studied in over 1,600 men at 76 medical centers worldwide. It is now being introduced by Merck.
 Merck scientists and experts in urology will present detailed information about benign prostate enlargement and Proscar. They will also be available for questions and individual interviews.
 CONTACT: Lee Bergman of Robert Marston and Associates, 212-371-2200, or home, 914-730-2009, for Merck; or Gary Bruell of Merck & Co., 215-661-6681, or home, 215-368-7328.
 -0- 6/20/92 R
 (MRK) CO: Merck & Co., Inc. ST: Pennsylvania IN: MTC SU: PDT


GK -- NYSA008R -- 2204 06/22/92 07:45 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 22, 1992
Words:301
Previous Article:OPTICAL DEVICE ENABLES SOME WITH MACULAR DEGENERATION TO DRIVE
Next Article:BARRY BRINK JOINS COOPERS & LYBRAND AS DIRECTOR OF VALUATION PRACTICE
Topics:


Related Articles
FDA COMMITTEE FAVORABLY REVIEWS MERCK PROSTATE DRUG
MERCK INTRODUCING NEW DRUG FOR SYMPTOMATIC BENIGN PROSTATE ENLARGEMENT
FIRST ADD TO MERCK ANNOUNCES PROGRAM FOR PATIENTS ON PROSCAR
FDA APPROVES PROSTATE DRUG
PROSCAR(R) NOW AVAILABLE IN U.S. PHARMACIES; NEW DRUG TREATS COMMON PROSTATE PROBLEM IN OLDER MEN
ABBOTT, MERCK AND VA TO FUND COOPERATIVE STUDY FOR THE TREATMENT OF BPH
MERCK'S PROSCAR BEING STUDIED IN VETERAN'S AFFAIRS TREATMENT TRIAL FOR SYMPTOMATIC BENIGN PROSTATE ENLARGEMENT
RECOGNIZING EXCELLENCE IN INNOVATION, IDENTIFYING HEROES; MERCK RESEARCHERS RECEIVE 1993 INVENTOR OF YEAR AWARD FOR BREAKTHROUGH DRUG
Proscar Reduced Surgery and Urinary Retention in Study of Men With Benign Prostate Enlargement
FDA Clears Merck's Proscar to Reduce Need for Prostate Surgery and Risk Of Urinary Retention in Men Suffering from Enlarged Prostates

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters